Neuphoria Therapeutics (NEUP) Invested Capital (2020 - 2026)

Neuphoria Therapeutics (NEUP) has 7 years of Invested Capital data on file, last reported at $29.4 million in Q1 2026.

• Quarterly Invested Capital rose 13.18% year-over-year to $29.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (up 13.18% YoY) and the FY2025 annual result came in at $19.0 million, up 8.65% from the prior year.
• Invested Capital eased to $29.4 million in Q1 2026 per NEUP's latest filing, from $29.7 million in the prior quarter.
• Across five years, Invested Capital topped out at $40.8 million in Q2 2022 and bottomed at $12.5 million in Q3 2025.
• The 5-year median for Invested Capital is $19.0 million (2025), against an average of $21.7 million.
• The widest annual swing landed in 2023, when Invested Capital plunged 45.65%; it then jumped 116.04% in 2025.
• Tracing NEUP's Invested Capital over 5 years: stood at $40.8 million in 2022, then tumbled by 52.17% to $19.5 million in 2023, then dropped by 29.49% to $13.7 million in 2024, then jumped by 116.04% to $29.7 million in 2025, then declined by 0.93% to $29.4 million in 2026.
• Per Business Quant, the three latest NEUP Invested Capital figures stand at $29.4 million (Q1 2026), $29.7 million (Q4 2025), and $12.5 million (Q3 2025).

Peer Comparison